Details of the Drug

General Information of Drug (ID: DMMTAJC)

Drug Name
Potassium Chloride
Synonyms
Acronitol; Celeka; Chloropotassuril; Chlorvescent; Durekal; Durules; Enpott; Enseal; Infalyte; KCL; KSR; Kadalex; Kalcorid; Kaleorid; Kaleorod; Kaliduron; Kaliglutol; Kalilente; Kalinorm; Kaliolite; Kalipor; Kalipoz; Kalitabs; Kaliumchlorid; Kaochlor; Kaskay; Kato; Kayback; Kayciel; Kaysiel; Keylyte; Kloren; Klorvess; Klotrix; Kolyum; Miopotasio; Neobakasal; Pfiklor; Potasion; Potasol; Potavescent; Rekawan; Selora; Steropotassium; Sylvite; [KCl]; Chlorid draselny; Chlorid draselny [Czech]; Chloride of potash; Conductance standard solution; Dipotassium dichloride; Emplets potassium chloride; K Tab; KCL Retard; KM potassium chloride; Kalinorm Depottab; Kalitrans Retard; Kalium Duriles; Kalium Durules; Kalium Retard; Kalium SR; Kaon Cl; Kaon Ultra; Kay Ciel; Kelp salt; Leo K; Monopotassium chloride; Muriate of potash; Natural sylvite; Plus Kalium Retard; Potassium Chloride BP; Potassium Chloride in Plastic Container; Potassium Cl; Potassium chloride [JAN]; Potassium chloride solution; Potassium chloride standard; Potassium monochloride; Potassium muriate; Rekawan Retard; Repone K; Sal digestnum sylvii; Super K; Tripotassium trichloride; Trona muriate of potash; Trona potassium chloride; Ultra K Chlor; IN2900; Potassium Chloride 10meq in Plastic Container; Potassium chloride 20meq inplastic container; Potassium chloride 30meq in plastic container; Potassium chloride 40meq in plastic container; Addi-K; Apo-K; Cena-K; Chloride, Potassium; Chloropotassuril diffu-K; Diffu-K; Duffi-K; Durules-K; K+10; K+8; K-10; K-Care; K-Contin; K-Dur; K-Grad; K-Lease; K-Lor; K-Lyte Cl; K-Norm; K-SR; K-Sol; K-Tab; K. tab; KCL (TN); KCl-retard Zyma; Kalinor-Retard P; Kalium S.R; Kalium-Durettes; Kalium-R; Kalium-duriles; Kaon Cl-10; Kaon-Cl; Kaon-Cl 10; Kaon-Cl TABS; Kaon-ci; Kay-Ciel; Kay-EM; Klor-Con; Klor-Con M10; Klor-Con M15; Klor-Con M20; Klor-Lyte; Klotrix (TN); Lento-K; Lento-Kalium; Leo-K; Micro-K; Micro-K 10; Micro-K Extentcaps; Micro-K LS; Micro-Kalium Retard; Nu-K; POTASSIUM CHLORIDE, ACS; Peter-kal; Potassium atomic spectroscopy standard concentrate 1.00 g K; Potassium chloride (K3Cl3); Potassium chloride (KCl); Potassium standard concentrate 10.00 g K; Potassium thallium chloride (KTlCl); Repone-K; Rum-K; Sando-K; Slow-K; Slow-K tablets; Span-K; Super K (salt); Ten-K; Clor-K-Zaf; Hydrochloric acid potassium salt (1:1); ISA (ionic strength adjustment solution: 1 M KCl); K-Lyte/Cl; K-Predne-Dome; K-dur (TN); K-lyte/C1; Kalium S.R.; Kaon-Cl (TN); Kay-Cee-L; Klor-con (TN); Potassium chloride (JP15/USP); Ultra-K-Chlor; Conductivity Standard Solution, 1413-S/cm; Conductivity Standard Solution, 500-S/cm; POTASSIUM CHLORIDE, U.S.P.; 11118_FLUKA
Indication
Disease Entry ICD 11 Status REF
Hypokalemia 5C77 Approved [1]
Therapeutic Class
Dietary supplement
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 74.55
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 0
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 1
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Elimination
85% of drug is excreted from urine in the unchanged form [2]
Water Solubility
The ability of drug to dissolve in water is measured as 333.3 mg/mL [2]
Chemical Identifiers
Formula
ClK
IUPAC Name
potassium;chloride
Canonical SMILES
[Cl-].[K+]
InChI
InChI=1S/ClH.K/h1H;/q;+1/p-1
InChIKey
WCUXLLCKKVVCTQ-UHFFFAOYSA-M
Cross-matching ID
PubChem CID
4873
ChEBI ID
CHEBI:32588
CAS Number
7447-40-7
DrugBank ID
DB00761
TTD ID
D0E9JM
VARIDT ID
DR00184
ACDINA ID
D00543
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Solute carrier family 12 member 1 (SLC12A1) TTS087L S12A1_HUMAN Modulator [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Electroneutral potassium-chloride cotransporter 3 (SLC12A6) DTMA4FJ S12A6_HUMAN Substrate [4]
Electroneutral potassium-chloride cotransporter 2 (SLC12A5) DTD62VB S12A5_HUMAN Substrate [5]
Electroneutral potassium-chloride cotransporter 1 (SLC12A4) DTY25IU S12A4_HUMAN Substrate [6]
Basolateral Na-K-Cl symporter (SLC12A2) DTHKL3Q S12A2_HUMAN Substrate [7]
Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2 (SLC12A1) DTO1UQY S12A1_HUMAN Substrate [8]
Organic cation/carnitine transporter 2 (SLC22A5) DT3HUVD S22A5_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 11B1, mitochondrial (CYP11B1) OTKKL894 C11B1_HUMAN Gene/Protein Processing [10]
Cytochrome P450 11B2, mitochondrial (CYP11B2) OTIOLWYN C11B2_HUMAN Gene/Protein Processing [10]
Kallikrein-8 (KLK8) OTGVGHXY KLK8_HUMAN Gene/Protein Processing [11]
Lipoprotein lipase (LPL) OTTW0267 LIPL_HUMAN Drug Response [12]
Nuclear receptor subfamily 4immunitygroup A member 1 (NR4A1) OTGP6GA4 NR4A1_HUMAN Gene/Protein Processing [13]
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Gene/Protein Processing [14]
Protein FosB (FOSB) OTW6C05J FOSB_HUMAN Gene/Protein Processing [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Potassium Chloride (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Mepyramine DMB4SFH Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [15]
Phenyltoloxamine DMKAEQW Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [15]
Desipramine DMT2FDC Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Desipramine. Attention deficit hyperactivity disorder [6A05] [16]
Phenylbutazone DMAYL0T Moderate Increased risk of hyperkalemia by the combination of Potassium chloride and Phenylbutazone. Chronic pain [MG30] [17]
Ketoprofen DMRKXPT Moderate Increased risk of hyperkalemia by the combination of Potassium chloride and Ketoprofen. Chronic pain [MG30] [17]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Potassium chloride and Drospirenone. Contraceptive management [QA21] [18]
Cyclobenzaprine DM1YBRM Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Cyclobenzaprine. Depression [6A70-6A7Z] [16]
Clomipramine DMINRKW Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Clomipramine. Depression [6A70-6A7Z] [16]
Doxepin DMPI98T Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Doxepin. Depression [6A70-6A7Z] [15]
Mefenamic acid DMK7HFI Moderate Increased risk of hyperkalemia by the combination of Potassium chloride and Mefenamic acid. Female pelvic pain [GA34] [17]
Eprosartan DM07K2I Major Increased risk of hyperkalemia by the combination of Potassium chloride and Eprosartan. Hypertension [BA00-BA04] [19]
Aliskiren DM1BV7W Moderate Increased risk of hyperkalemia by the combination of Potassium chloride and Aliskiren. Hypertension [BA00-BA04] [20]
Captopril DM458UM Major Increased risk of hyperkalemia by the combination of Potassium chloride and Captopril. Hypertension [BA00-BA04] [21]
TAK-491 DMCF6SX Major Increased risk of hyperkalemia by the combination of Potassium chloride and TAK-491. Hypertension [BA00-BA04] [19]
Perindopril DMOPZDT Major Increased risk of hyperkalemia by the combination of Potassium chloride and Perindopril. Hypertension [BA00-BA04] [21]
Quinapril DMR8H31 Major Increased risk of hyperkalemia by the combination of Potassium chloride and Quinapril. Hypertension [BA00-BA04] [21]
Telmisartan DMS3GX2 Major Increased risk of hyperkalemia by the combination of Potassium chloride and Telmisartan. Hypertension [BA00-BA04] [19]
Irbesartan DMTP1DC Major Increased risk of hyperkalemia by the combination of Potassium chloride and Irbesartan. Hypertension [BA00-BA04] [22]
Tolvaptan DMIWFRL Moderate Increased risk of hyperkalemia by the combination of Potassium chloride and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [23]
Meclofenamic acid DM05FXR Moderate Increased risk of hyperkalemia by the combination of Potassium chloride and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [24]
Clidinium DMUMQZ0 Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Clidinium. Irritable bowel syndrome [DD91] [16]
Dicyclomine DMZSDGX Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Dicyclomine. Irritable bowel syndrome [DD91] [16]
Promethazine DM6I5GR Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Promethazine. Nausea/vomiting [MD90] [16]
Diflunisal DM7EN8I Moderate Increased risk of hyperkalemia by the combination of Potassium chloride and Diflunisal. Pain [MG30-MG3Z] [17]
Ibuprofen DM8VCBE Moderate Increased risk of hyperkalemia by the combination of Potassium chloride and Ibuprofen. Pain [MG30-MG3Z] [17]
Biperiden DME78OA Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Biperiden. Parkinsonism [8A00] [16]
Orphenadrine DMW542E Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Orphenadrine. Parkinsonism [8A00] [16]
Bromfenac DMKB79O Moderate Increased risk of hyperkalemia by the combination of Potassium chloride and Bromfenac. Postoperative inflammation [1A00-CA43] [17]
Meloxicam DM2AR7L Moderate Increased risk of hyperkalemia by the combination of Potassium chloride and Meloxicam. Rheumatoid arthritis [FA20] [17]
Oxaprozin DM9UB0P Moderate Increased risk of hyperkalemia by the combination of Potassium chloride and Oxaprozin. Rheumatoid arthritis [FA20] [17]
Molindone DMAH70G Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Molindone. Schizophrenia [6A20] [16]
Brompheniramine DMFOVSD Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [16]
Acrivastine DMTIGA0 Major Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Acrivastine. Vasomotor/allergic rhinitis [CA08] [16]
⏷ Show the Full List of 33 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Alpha-tocopherol E00243 14985 Antimicrobial preservative; Antioxidant
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Oleic acid E00421 445639 Emulsifying agent; Penetration agent; Solubilizing agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Vanillin E00049 1183 Flavoring agent
Acetyltributyl citrate E00127 6505 Plasticizing agent
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Calcium stearate E00244 15324 lubricant
Carmellose sodium E00625 Not Available Disintegrant
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone E00626 Not Available Disintegrant
Dibutyl sebacate E00160 7986 Plasticizing agent
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 1000 E00647 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Water E00035 962 Solvent
⏷ Show the Full List of 37 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Potassium chloride 10 meq tablet 10 meq Extended Release Oral Tablet Oral
Potassium chloride 8 meq tablet 8 meq Extended Release Oral Tablet Oral
Potassium chloride 10 meq capsule 10 meq Extended Release Oral Capsule Oral
Potassium chloride 20 meq tablet 20 meq Extended Release Oral Tablet Oral
Potassium chloride 8 meq capsule 8 meq Extended Release Oral Capsule Oral
Potassium chloride 1500 mg tablet 1500 mg Extended Release Tablet Oral
Potassium chloride 750 mg tablet 750 mg Extended Release Tablet Oral
Potassium chloride 10 meq tablet 10 meq Extended Release Tablet Oral
Potassium chloride 20 meq tablet 20 meq Extended Release Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070999.
2 BDDCS applied to over 900 drugs
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Functional analysis of a potassium-chloride co-transporter 3 (SLC12A6) promoter polymorphism leading to an additional DNA methylation site. Neuropsychopharmacology. 2009 Jan;34(2):458-67.
5 Tyrosine phosphorylation regulates the membrane trafficking of the potassium chloride co-transporter KCC2. Mol Cell Neurosci. 2010 Oct;45(2):173-9.
6 Human potassium chloride cotransporter 1 (SLC12A4) promoter is regulated by AP-2 and contains a functional downstream promoter element. Blood. 2004 Jun 1;103(11):4302-9.
7 Expression of the sodium potassium chloride cotransporter (NKCC1) and sodium chloride cotransporter (NCC) and their effects on rat lens transparency. Mol Vis. 2010 May 4;16:800-12.
8 Rare mutations in renal sodium and potassium transporter genes exhibit impaired transport function. Curr Opin Nephrol Hypertens. 2014 Jan;23(1):1-8.
9 Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch. 2010 Jul;460(2):505-23.
10 Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol. 2008 Apr 28;584(2-3):424-34. doi: 10.1016/j.ejphar.2008.02.001. Epub 2008 Feb 12.
11 Activation and enzymatic characterization of recombinant human kallikrein 8. Biol Chem. 2006 Jun;387(6):723-31. doi: 10.1515/BC.2006.091.
12 Tissue-specific expression of human lipoprotein lipase in the vascular system affects vascular reactivity in transgenic mice. Br J Pharmacol. 2002 Jan;135(1):143-54. doi: 10.1038/sj.bjp.0704440.
13 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
14 Different populations of progesterone receptor-steroid complexes in binding to specific DNA sequences: effects of salts on kinetics and specificity. J Steroid Biochem Mol Biol. 1998 Nov;67(3):251-66. doi: 10.1016/s0960-0760(98)00118-6.
15 Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8. [PMID: 4013604]
16 Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
17 Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
18 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
19 Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12. [PMID: 6744599]
20 Product Information. Tekturna (aliskiren). Novartis Pharmaceuticals, East Hanover, NJ.
21 Product Information. K-Dur (potassium chloride). Schering Laboratories, Kenilworth, NJ.
22 Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902]
23 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
24 Product Information. K-Phos Original (potassium acid phosphate). Beach Pharmaceuticals, Tampa, FL.